Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates - GlobeNewswire

Retrieved on: 2023-10-21 18:51:50

Tags for this article:

Breakthrough therapy

Cemiplimab

Sanofi

Lung cancer

Regeneron Pharmaceuticals

Squamous-cell carcinoma

Radiation therapy

Clinical endpoint

PD-1 and PD-L1 inhibitors

Adenocarcinoma of the lung

Regeneron Pharmaceuticals Inc.

Click the tags to see associated articles and topics

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2023/10/21/2764294/0/en/Libtayo-cemiplimab-Neoadjuvant-Treatment-Demonstrates-Encouraging-Event-Free-Survival-in-Patients-with-Resectable-Cutaneous-Squamous-Cell-Carcinoma-CSCC.html

Excerpt

have immune system problems such as Crohn's disease, ulcerative colitis, or lupus · have received an organ transplant ...

Article found on: www.globenewswire.com

View Original Article